DOCSLIB.ORG

R.E.7. SSS"'5, Transdermally Administered Pharmacologically Or

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
R.E.7. SSS USOO6835392B2 (12) United States Patent (10) Patent No.: US 6,835,392 B2 Hsu et al. (45) Date of Patent: Dec. 28, 2004 (54) DUAL ENHANCER COMPOSITION FOR 5,071,657. A 12/1991 Oloff et al. TOPCAL AND TRANSIDERMAL DRUG 5,152.997 A 10/1992 Ebert et al. DELIVERY 5,318,960 A 6/1994 Toppo 5,432,192 A 7/1995 Sawanishi et al. (75) Inventors: Tsung-Min Hsu, San Diego, CA (US); (List continued on next page.) Eric C. Jacobson, San Diego, CA (US); Rose C. LoBello, San Diego, CA FOREIGN PATENT DOCUMENTS (US); Eric C. Luo, Plano, TX (US) EP O276561 8/1988 (73) Assignee: Dermatrends, Inc., San Diego, CA EP O316065 5/1989 (US) (List continued on next page.) (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S. patent application Ser. No. 09/465,098, Luo et al., filed (21) Appl. No.: 10/389,143 (List continued on next page.) (22) Filed: Mar 13, 2003 Primary Examiner Thurman K. Page 9 ASSistant Examiner-Isis Ghali (65) Prior Publication Data (74) Attorney, Agent, or Firm-Reed & Eberle LLP, US 2003/0161870 A1 Aug. 28, 2003 Dianne E. Reed; Shelley P. Eberle Related U.S. ApplicationO O Data (57) ABSTRACT A permeation enhancer composition is provided for increas (60) Division of application No. 09/972,008, filed on Oct. 4, ing the permeability of skin or mucosal tissue to topically or nowR.E.7. Pat. No. 6,586,000, which is aSSS"'5, continuation-in-part of ceuticallytransdermally active administered agents. The compositionpharmacologically is comprised or cosme: of a application No. 09/569,889, filed on May 11, 2000, now hydroxide-releasing agent and a lipophilic co-enhancer Such abandoned, which is a continuation-in-part of application as a fatty alcohol, a fatty ether, or a fatty acid ester, including No. 09/465,098, filed on Dec. 16, 1999, now abandoned. fatty acid esters of polyols Such as propylene glycol and (51) Int. Cl. .......................... A61F 13/00; A61L 15/00 glycerol. Also provided are pharmaceutical formulations (52) U.S. Cl. ....................... 424/449, 424/443; 424/445, containing a therapeutically effective amount of an active 424/447: 424/44s. 514/946. 514/944 agent in addition to the aforementioned enhancer (58) Field of Search s s 424A49, 443 composition, methods for administering active agents topi 424,445,447,448. 514/946, 9 47.944 cally or transdermally with enhanced permeation, and drug s Y-s s 1 s delivery Systems for application to an individual’s skin or (56) References Cited mucosal tissue, wherein the Systems are formulated So as to contain an active agent to be administered and an effective U.S. PATENT DOCUMENTS permeation enhancing amount of an enhancer composition of the invention. 4,704,282 A 11/1987 Campbell et al. 4,789,547 A 12/1988 Song et al. 4,837,027 A 6/1989 Lee et al. 48 Claims, 1 Drawing Sheet Human Skin Permeation of testosterone from a Matrix Patch 0,4 Tast-19 0.346 mgicrT2 0.35 O), 3 est-180 0.254 mg.cm2 , 25 0, 2 0.15 0, es-P181 0.05 0.051 mglom2 est-8 0.44 mg.cm2. --- O s O 15 20 25 3. time hours) US 6,835,392 B2 Page 2 U.S. PATENT DOCUMENTS 6,004,577 A 12/1999 Murdock 6,019,988 A 2/2000 Parab et al. 5,446,070 A 8/1995 Mantelle 6,019.997 A 2/2000 Scholz et al. 5,460.820 A 10/1995 Ebert et al. 6,123,961 A 9/2000 Aberg 5,462,744. A 10/1995 Gupte et al. 6,132,760 A 10/2000 Hedenstrom et al. 5,462,746 A 10/1995 Wolter et al. 6,139,866 A 10/2000 Chono et al. 5,474,783 A 12/1995 Miranda et al. 6,174,546 B1 1/2001 Therriault et al. 5,498,417 A 3/1996 Lhila et al. 6,204.268 B1 3/2001 Scarborough et al. 5,500.222 A 3/1996 Lee et al. 6.214.374 B1 4/2001 Schmirler et al. 5,527,832 A 6/1996 Chi et al. 6,316,011 B1 11/2001 Ron et al. 5.532.278 A 7/1996 Aberg et al. 5,534,496 A 7/1996 Lee et al. FOREIGN PATENT DOCUMENTS 5,562.917. A 10/1996 Durif et al. 5,573,778 A 11/1996 Therriault et al. EP O709088 5/1996 5,599,554 A 2/1997 Majeti EP O842662 5/1998 5,614,211 A 3/1997 Gale et al. FR 2692145 12/1993 5,674,895 A 10/1997 Guittard et al. JP 218O835 7/1990 5,807,568 A 9/1998 Cody et al. JP 6092843 4/1994 5,817,332 A 10/1998 Urtti et al. KR 9507098 6/1995 5.830,497 A 11/1998 Yamanaka et al. WO WO 94/21271 9/1994 5,834,513 A 11/1998 Ptchelintsev et al. WO WO 99/49844 10/1999 5,847,003 A 12/1998 Ptchelintsev et al. 5,879,690 A 3/1999 Perricone OTHER PUBLICATIONS 5,939,094. A 8/1999 Durif et al. 5.962,018 A 10/1999 Curtis et al. U.S. patent application Ser. No. 09/569,889, Luo et al., filed 5,985,317 A 11/1999 Venkateshwaran et al. May 11, 2000. A A. Toppo Aungst et al. (1990), “Contributions of Drug Solubilization, 5.990,1132- Y - 2 A 11/1999f1999 YamazakiHsu et al. et al. Partitioning, Barrier Disruption, and Solvent Permeation to 5.990,179 A 11/1999 Gyory et al. the Enhancement of Skin Permeation of Various Compounds 5,993,851 A 11/1999 Foldvari with Fatty Acids and Amines, Pharmaceutical Research 5,994,372 A 11/1999 Yaksh 7(7):712-718. U.S. Patent Dec. 28, 2004 US 6,835,392 B2 N cN 2 Y. ed o o (zuoyfu) euouasosal go unouw aaen uno US 6,835,392 B2 1 2 DUAL ENHANCER COMPOSITION FOR skin permeability include: Sulfoxides Such as dimethylsul TOPCAL AND TRANSIDERMAL DRUG foxide (DMSO) and decylmethylsulfoxide (CMSO); DELIVERY ethers such as diethylene glycol monoethyl ether (available commercially as TranscutolCE) and diethylene glycol CROSS-REFERENCE TO RELATED monomethyl ether, Surfactants Such as Sodium laurate, APPLICATIONS Sodium lauryl Sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween This is a divisional of U.S. patent application Ser. No. (20, 40, 60,80) and lecithin (U.S. Pat. No. 4,783,450); the 09/972,008, filed Oct. 4, 2001, and now issued as U.S. Pat. 1-Substituted azacycloheptan-2-ones, particularly 1-n- No. 6,582,724; which is a continuation-in-part of U.S. patent dodecyl-cyclazacycloheptan-2-one (available under the application Ser. No. 09/738,410, filed Dec. 14, 2000, and trademark AZone(R) from Nelson Research & Development now issued as U.S. Pat. No. 6,586,000; which was a continuation-in-part of U.S. patent application Ser. No. Co., Irvine, Calif.; see U.S. Pat. Nos. 3,989.816, 4,316,893, 09/569,889, filed May 11, 2000, now abandoned; which was 4,405,616 and 4,557,934); alcohols such as ethanol, a continuation-in-part of U.S. patent application Ser. No. propanol, octanol, benzyl alcohol, and the like; fatty acids 15 Such as lauric acid, oleic acid and Valeric acid; fatty acid 09/465,098, filed Dec. 16, 1999, now abandoned; the dis esterS Such as isopropyl myristate, isopropyl palmitate, closures of which are incorporated by reference. methylpropionate, and ethyl oleate; polyols and esters thereof Such as propylene glycol, ethylene glycol, glycerol, TECHNICAL FIELD butanediol, polyethylene glycol, and polyethylene glycol This invention relates generally to the topical and trans monolaurate (PEGML; see, e.g., U.S. Pat. No. 4,568,343); dermal administration of pharmacologically active agents, amides and other nitrogenous compounds Such as urea, and more particularly relates to permeation enhancer com dimethylacetamide (DMA), dimethylformamide (DMF), positions for enhancing the permeability of skin or mucosal 2-pyrrollidone, 1-methyl-2-pyrrollidone, ethanolamine, tissue to topically applied pharmacologically active agents. diethanolamine and triethanolamine; terpenes, alkanones, 25 and organic acids, particularly Salicylic acid and Salicylates, BACKGROUND ART citric acid and Succinic acid. Percutaneous Penetration Skin is a structurally complex, relatively thick membrane. Enhancers, eds. Smith et al. (CRC Press, 1995) provides an In order to deliver a drug into and through the skin, i.e., excellent overview of the field and further background “transdermally, drug molecules must first penetrate the information on a number of chemical and physical enhanc Stratum corneum and any material on its Surface. They must CS. then penetrate the viable epidermis, the papillary dermis, Although many chemical permeation enhancers are and the capillary walls into the blood stream or lymph known, there is an ongoing need for enhancers that are channels. To be So absorbed, molecules must overcome a highly effective in increasing the rate at which a drug different resistance to penetration in each type of tissue. permeates the skin, do not result in Skin damage, irritation, Transport across the Skin membrane is thus a complex 35 Sensitization, or the like, and can be used to effect transder phenomenon. However, it is the cells of the Stratum corneum mal delivery of even high molecular weight drugs. Such as that present the primary barrier to absorption of topical peptides, proteins, and nucleic acids. Furthermore, it would compositions or transdermally administered drugs.
Load more

Recommended publications
  • Dilantin (Phenytoin Sodium) Extended Oral Capsule Three Times Daily and the Dosage Then Adjusted to Suit Individual Requirements
    Dilantin® (Phenytoin Sodium) 100 mg Extended Oral Capsule DESCRIPTION Phenytoin sodium is an antiepileptic drug. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is sodium 5,5-diphenyl-2, 4-imidazolidinedione, having the following structural formula: Each Dilantin— 100 mg Extended Oral Capsule—contains 100 mg phenytoin sodium. Also contains lactose monohydrate, NF; confectioner’s sugar, NF; talc, USP; and magnesium stearate, NF. The capsule body contains titanium dioxide, USP and gelatin, NF. The capsule cap contains FD&C red No. 28; FD&C yellow No. 6; and gelatin NF. Product in vivo performance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to Prompt Phenytoin Sodium Capsules, USP with a rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours. CLINICAL PHARMACOLOGY Phenytoin is an antiepileptic drug which can be used in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
    [Show full text]
  • Chapter Four – TRPA1 Channels: Chemical and Temperature Sensitivity
    CHAPTER FOUR TRPA1 Channels: Chemical and Temperature Sensitivity Willem J. Laursen1,2, Sviatoslav N. Bagriantsev1,* and Elena O. Gracheva1,2,* 1Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA 2Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT, USA *Corresponding author: E-mail: [email protected], [email protected] Contents 1. Introduction 90 2. Activation and Regulation of TRPA1 by Chemical Compounds 91 2.1 Chemical activation of TRPA1 by covalent modification 91 2.2 Noncovalent activation of TRPA1 97 2.3 Receptor-operated activation of TRPA1 99 3. Temperature Sensitivity of TRPA1 101 3.1 TRPA1 in mammals 101 3.2 TRPA1 in insects and worms 103 3.3 TRPA1 in fish, birds, reptiles, and amphibians 103 3.4 TRPA1: Molecular mechanism of temperature sensitivity 104 Acknowledgments 107 References 107 Abstract Transient receptor potential ankyrin 1 (TRPA1) is a polymodal excitatory ion channel found in sensory neurons of different organisms, ranging from worms to humans. Since its discovery as an uncharacterized transmembrane protein in human fibroblasts, TRPA1 has become one of the most intensively studied ion channels. Its function has been linked to regulation of heat and cold perception, mechanosensitivity, hearing, inflam- mation, pain, circadian rhythms, chemoreception, and other processes. Some of these proposed functions remain controversial, while others have gathered considerable experimental support. A truly polymodal ion channel, TRPA1 is activated by various stimuli, including electrophilic chemicals, oxygen, temperature, and mechanical force, yet the molecular mechanism of TRPA1 gating remains obscure. In this review, we discuss recent advances in the understanding of TRPA1 physiology, pharmacology, and molecular function.
    [Show full text]
  • Cannabinoid Receptor and Inflammation
    Cannabinoid Receptor and Inflammation Newman Osafo1, Oduro Yeboah1, Aaron Antwi1, and George Ainooson1 1Kwame Nkrumah University of Science and Technology September 11, 2020 Abstract The eventual discovery of endogenous cannabinoid receptors CB1 and CB2 and their endogenous ligands has generated interest with regards to finally understanding the endocannabinoid system. Its role in the normal physiology of the body and its implication in pathological states such as cardiovascular diseases, neoplasm, depression and pain have been subjects of scientific interest. In this review the authors focus on the endogenous cannabinoid pathway, the critical role of cannabinoid receptors in signaling and mediation of neurodegeneration and other inflammatory responses as well as its potential as a drug target in the amelioration of some inflammatory conditions. Though the exact role of the endocannabinoid system is not fully understood, the evidence found leans heavily towards a great potential in exploiting both its central and peripheral pathways in disease management. Cannabinoid therapy has already shown great promise in several preclinical and clinical trials. 1.0 Introduction Ethnopharmacological studies have shown the use of Cannabis sativa in traditional medicine for over a thousand years, with its widespread use promoted by its psychotropic effects (McCoy, 2016; Turcotte et al., 2016). The discovery of a receptor within human body, that is selectively activated by cannabinoids suggested the presence of at least one endogenous ligand for this receptor. This is confirmed by the discovery of two endogenously synthesized lipid mediators, 2-arachidonoyl-glycerol and arachidonoylethanolamide, which function as high-affinity ligands for a subfamily of cannabinoid receptors ubiquitously distributed in the central nervous system, known as the CB1 receptors (Turcotte et al., 2016).
    [Show full text]
  • THE SPECIFICITY of DRUG BINDING SITES on HUMAN SERUM ALBUMIN Ingvar Sjòholm
    THE SPECIFICITY OF DRUG BINDING SITES ON HUMAN SERUM ALBUMIN Ingvar Sjòholm Today, it is well established that the binding of drugs in serum will strongly influence the pharmacokinetic parameters of a drug, such as its distribution volume and clearance. It is also evident that the binding of the drug—in serum and elsewhere in the tissues—will have an influence on the duration and intensity of the pharmacological effect. Several excellent papers and reviews have dealt with these issues in recent years.1"** It is obvious that albumin, being the most abundant protein species in the extracellular fluids, is the most im- portant drug-binding protein, although other proteins can play a pharmacokinetic role. Thus, e.g., orosomucoid (aj-acid glyco- protein) can bind some basic and neutral drugs ,9 and lipoproteins some highly hydrophobic drugs.10 The primary structure of human serum albumin (HSA) is now known.1:L'^2 However, all efforts to study the three-dimensional structure by x-ray spectroscopy have hitherto failed, and a detailed knowledge of the mechanisms involved in the binding of drugs or endogenous compounds is still missing. The broad binding specificity of HSA is remarkable. Several compounds of widely different struc- ture can be bound with high affinity—e.g., fatty acids, bilirubin, tryptophan, as well as many drugs. It is also striking that different reports from quantitative studies on the binding of different com- pounds have shown varying results, which cannot be solely explained by technical problems or different experimental conditions. All avail- able information indicates that HSA is a highly "flexible" and "adapt- able" molecule, the structure of which can be strongly influenced by different "modulating" substances.
    [Show full text]
  • N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation Via Nonhematopoietic TRPV1
    N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1 This information is current as Samira K. Lawton, Fengyun Xu, Alphonso Tran, Erika of October 1, 2021. Wong, Arun Prakash, Mark Schumacher, Judith Hellman and Kevin Wilhelmsen J Immunol 2017; 199:1465-1475; Prepublished online 12 July 2017; doi: 10.4049/jimmunol.1602151 http://www.jimmunol.org/content/199/4/1465 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/07/12/jimmunol.160215 Material 1.DCSupplemental http://www.jimmunol.org/ References This article cites 69 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/199/4/1465.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 1, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1 Samira K.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Decreased Serum Concentrations of Tamoxifen and Its Metabolites Induced by Aminoglutethimide1
    (CANCER RESEARCH 50. 5851-5857. September 15. 1990) Decreased Serum Concentrations of Tamoxifen and Its Metabolites Induced by Aminoglutethimide1 Ernst A. Lien,2 Gun Anker, Per Eystein Lgnning, Einar Solheim, and Per M. Ueland Department i>j'Pharmacology and Toxicology [E. A. I... E. S]; Clinical Pharmacology I nit. Department of Pharmacology and Toxicology /P. M. l './; and Department of Oncology I(i. A., P. fi. Lj, L'niversity of Bergen, .\-502l, Bergen, \onvay ABSTRACT Aminoglutethimide inhibits the enzyme aromatase, which converts androgens to estrogens in peripheral fat tissue (3). The anticstrogen tamoxifen and the aromatase inhibitor aminoglute- This conversion is the main estrogen source in postmenopausal thimide show similar response rates when used in the endocrine manage women. In addition, aminoglutethimide may reduce the con ment of advanced breast cancer. However, numerous clinical trials have centration of plasma estrogens by enhancement of estrogen demonstrated no increase in response rate from treatment with the drug combination of tamoxifen plus aminoglutethimide. We investigated the metabolism (10, 11). Aminoglutethimide causes response rates possibility of a pharmacokinetic interaction between these two drugs in in postmenopausal breast cancer patients similar to those of six menopausa! woman with breast cancer. All patients were investigated tamoxifen, but because of more frequent side effects aminoglu under three different conditions (termed phases A, B, and C). The steady tethimide is generally used after tamoxifen as a second line state kinetics of tamoxifen were determined when administered alone endocrine treatment (12). (phase A) and after coadministration of aminoglutethimide for 6 weeks Combination therapy with tamoxifen plus aminoglutethi (phase B).
    [Show full text]
  • Pharmacology for PAIN: Prescribing Controlled Substances
    The Impact of Pain Pharmacology for PAIN: The National Center for Health Prescribing Controlled Statistics estimates that 32.8% of the U.S. population has persistent pain ~94 million U.S. residents have episodic or Substances persistent pain (1 in every 5 adults) Judith A. Kaufmann, Dr PH, FNP-BC Treatment for chronic pain rarely Robert Morris University results in complete relief and full functional recovery Of patients diagnosed with chronic pain and treated by a PCP, 64 percent report persistent pain two years after treatment initiation US Statistics: The Alarming Impact of Pain Facts Pain ranks low on medical tx priority Americans constitute 4.6% of world’s only 15% of primary care physicians report that they "enjoy" treating patients with chronic pain population-but consume ~ 80% of world’s Dahl et al., and Redford (2002) found that patients opioid supply said they fear dying in pain more than they fear death Americans consume 99% of world supply of hydrocodone Pain over the past 10 years has been designated the 5th vital sign Between 1999 and 2006, the number of people >age 12 using illicit prescription Pain is 3rd leading cause of absence pain relievers doubled from 2.6 to 5.2 from work million 2006 National Survey on Drug Use and Health (NSDUH) Are we the Pushers? Can we be found guilty? Since 1999, opioid analgesic poisonings on 55.7% of users obtained drugs from a death certificates increased 91% friend or relative who had been prescribed the drugs from 1 provider During same period, fatal heroin and cocaine poisonings increased 12.4% and 22.8% 19.1% of users obtained their drug directly respectively from 1 provider In 2008, 36,450 opioid deaths were 1.6% reported doctor shopping reported 3.9% reported purchasing drugs from a CDC, 2011 dealer Male:female ratio = 1.5:1 but death rate for females ia 20x higher than males 1 Is opioid abuse a recent Classifications of Pain phenomenon? Acute V.
    [Show full text]
  • Adverse Effects of Digoxin, As Xenoestrogen, on Some Hormonal and Biochemical Patterns of Male Albino Rats Eman G.E.Helal *, Mohamed M.M
    The Egyptian Journal of Hospital Medicine (October 2013) Vol. 53, Page 837– 845 Adverse Effects of Digoxin, as Xenoestrogen, on Some Hormonal and Biochemical Patterns of Male Albino Rats Eman G.E.Helal *, Mohamed M.M. Badawi **,Maha G. Soliman*, Hany Nady Yousef *** , Nadia A. Abdel-Kawi*, Nashwa M. G. Abozaid** Department of Zoology, Faculty of Science, Al-Azhar University (Girls)*, Department of Biochemistry, National organization for Drug Control and Research** Department of Biological and Geological Sciences, Faculty of Education, Ain Shams University*** Abstract Background: Xenoestrogens are widely used environmental chemicals that have recently been under scrutiny because of their possible role as endocrine disrupters. Among them is digoxin that is commonly used in the treatment of heart failure and atrial dysrhythmias. Digoxin is a cardiac glycoside derived from the foxglove plant, Digitalis lanata and suspected to act as estrogen in living organisms. Aim of the work: The purpose of the current study was to elucidate the sexual hormonal and biochemical patterns of male albino rats under the effect of digoxin treatment. Material and Methods: Forty six male albino rats (100-120g) were divided into three groups (16 rats for each). Half of the groups were treated daily for 15 days and the other half for 30 days. Control group: Animals without any treatment. Digoxin L group: orally received digoxin at low dose equivalent of 0.0045mg/200g.b.wt. Digoxin H group: administered digoxin orally at high dose equivalent of 0.0135mg/200g.b.wt. At the end of the experimental periods, blood was collected and serum was separated for estimation the levels of prolactin (PRL), FSH, LH, total testosterone (total T), aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), urea, creatinine, total proteins, albumin, total lipids, total cholesterol (total-chol), Triglycerides (TG), low density lipoprotein cholesterol (LDL-chol) and high density lipoprotein cholesterol (HDL-chol).
    [Show full text]
  • Transient Receptor Potential Cation Channel, Subfamily C, Member 5 (TRPC5) Is a Cold-Transducer in the Peripheral Nervous System
    Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system Katharina Zimmermanna,b,1,2, Jochen K. Lennerza,c,d,1,3, Alexander Heina,1,4, Andrea S. Linke, J. Stefan Kaczmareka,b, Markus Dellinga, Serdar Uysala, John D. Pfeiferc, Antonio Riccioa, and David E. Claphama,b,f,5 Departments of aCardiology, Manton Center for Orphan Disease, and bNeurobiology, Harvard Medical School, Boston, MA 02115; cDepartment of Pathology and Immunology, Washington University, St. Louis, MO, 63110; dDepartment of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, 02116; eDepartment of Physiology and Pathophysiology, University Erlangen, 91054 Erlangen, Germany; and fHoward Hughes Medical Institute, Harvard Medical School, Children’s Hospital Boston, Boston, MA 02115 Contributed by David E. Clapham, September 20, 2011 (sent for review August 9, 2011) Detection and adaptation to cold temperature is crucial to survival. affected perforce by temperature, even if driven solely by con- Cold sensing in the innocuous range of cold (>10–15 °C) in the ventional NaV and KV channels—but high Q10 channels are likely mammalian peripheral nervous system is thought to rely primarily suspects in encoding temperature changes. Although TRPM8 on transient receptor potential (TRP) ion channels, most notably (a menthol receptor) is generally considered the primary cold – the menthol receptor, TRPM8. Here we report that TRP cation sensor for innocuous cold (11 13), and TRPA1 participates in channel, subfamily C member 5 (TRPC5), but not TRPC1/TRPC5 het- noxious cold sensing (9, 10) (14), many cold-sensitive neurons eromeric channels, are highly cold sensitive in the temperature lack TRPM8 as well as TRPA1 (15).
    [Show full text]
  • A Critical Appraisal of a Further Three New Commercial Digoxin Radioimmunoassay Kits with Reference to Cross-Reacting Substances
    Wood and Wächter: Appraisal of three digoxin radioimmunoassay kits 77 J. Clin. Chern. Clin. Biochem. Vol. 17,1979, pp. 77-83 A Critical Appraisal of a Further Three New Commercial Digoxin Radioimmunoassay Kits with Reference to Cross-Reacting Substances By W. G. Wood and Christine Wächter Laboratorien für Klinische Chemie und Endokrinologie, Medizinische Klinik Innenstadt der Universität München (Received July 20/September 11, 1978) Summary: A further 3 digoxin radioimmunoassay (RIA) kits have been evaluated for performance and cross-reaction with digitoxin, spironolactone, canrenone and furosemide (Lasix-Hoechst). Effects of serum protein concentrations have also been tested. The kits tested were from the following manufacturers: A) Diagnostic Products Corporation Digoxin RIA Kit. B) Byk-Mallinckrodt SPAC Digoxin Kit. C) Boehringer-Mannheim Digoxin RIA Kit. All kits used a 125I-labelled tracer. Kit A used a conventional liquid phase system using double-antibody separation for bound and free drug, Kits B and C used a solid-phase antibody coated tube method. All kits showed a lower cross-reaction to digitoxin than quoted by the manufacturer. Cross-reaction to spironolactone (Aldactone — Boehringer-Mannheim) was less than 1.50 nmol/I at a serum concentra- tion of 125 mg/1 Aldactone in all 3 kits. The cross-reaction to canrenone was somewhat higher, 5.2 nmol/1 "digoxin" being measured in one kit at a serum canrenone concentration of 125 mg/1. There was no cross-reaction with furo- semide in any kit, even at ä serum concentration of 5 g/1. The coated-tube assays were affected by serum albumin and globulin concentration changes, one kit showing a difference of over 50% binding in the range 1—20% albumin.
    [Show full text]
  • Study Protocol, Statistical Analysis Plan, And
    Amendment Protocol Number: 04C0257-Q Reference Number: 366512 Principal Investigator: Ravi Madan NCI GMB 301.480.7168 [email protected] (NIH Employee Name, Institute/Branch, Telephone and e-mail) Protocol Title: A Phase II Trial of Docetaxel, Thalidomide, Prednisone, and Bevacizumab in Patients with Androgen-Independent Prostate Cancer SIGNATURES Principal Investigator (*): Ravi Madan - applied signature on 02/09/2017 9:47 AM EST Accountable Investigator: PI is the Accountable Investigator Branch Chief/CC Department Head (**): James L Gulley, MD PhD - applied signature on 02/06/2017 3:53 PM EST Medical Advisory Investigator (if applicable): N/A Lead Associate Investigator signature: N/A Referral Contact signatures: N/A Associate Investigators signatures: N/A For Institute/Center Scientific Review Committee: N/A Other IC Clinical Director signatures: N/A APPROVALS IRB Chair: Michael Hamilton - applied signature on 03/07/2017 7:58 PM EST Clinical Director: N/A CONCURRENCE OPS Protocol Specialist: Royal Reed AM Q 03/17/17 Signature Print Name Date * Signature signifies that investigators on this protocol have been informed that the collection and use of personally identifiable information at the NIH are maintained in a system of record governed under provisions of the Privacy Act of 1974. The information provided is mandatory for employees of the NIH to perform their assigned duties as related to the administration and reporting of intramural research protocols and used solely for those purposes. Questions may be addressed to the Protrak System Owner. ** I have reviewed this research project and considered the NIH Policy for Inclusion of Women and Minorities in Clinical Research.
    [Show full text]